Novo Nordisk reaches primary endpoint in phase III of once-weekly insulin

Novo Nordisk’s phase III study of insulin icodec, a once-weekly treatment for type 2 diabetes, has concluded, and the company reports that its primary goal was achieved.

Photo: Novo Nordisk / PR

Novo Nordisk has concluded a phase III study, dubbed Onwards 2, of once-weekly insulin icodec, the company has announced in a Thursday press release.

The drug was compared to Novo’s long-acting insulin degludec, which is sold under brand name Tresiba and administered once daily. According to results, icodec is as good as degludec.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs